Such a metabolic alteration appears to be the deregulated phospholipid metabolism that leads to an increased amount of LPA as evidenced by the observed increased ATX and LPA levels in the circulation of obese, T2DM and NAFLD patients [27,148,186,187,188,189]. Here, ENPP2 is linked to metabolic dysfunction-associated steatotic liver disease.